Evaluation of host genetics on outcome of tuberculosis infection due to differences in killer immunoglobulin-like receptor gene frequencies and haplotypes.

Publisher: BioMed Central Country of Publication: England NLM ID: 100966978 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2156 (Electronic) Linking ISSN: 14712156 NLM ISO Abbreviation: BMC Genet Subsets: MEDLINE

Original Publication: London : BioMed Central, [2000-

Gene Frequency* ; Haplotypes*; Host-Pathogen Interactions/*genetics ; Receptors, KIR/*genetics ; Tuberculosis/*epidemiology ; Tuberculosis/*genetics; Adolescent ; Adult ; Aged ; Canada/epidemiology ; Cross-Sectional Studies ; Female ; Genetic Predisposition to Disease ; Host-Pathogen Interactions/immunology ; Humans ; Male ; Middle Aged ; Mycobacterium tuberculosis/immunology ; Patient Outcome Assessment ; Tuberculosis/immunology ; Tuberculosis/microbiology ; Young Adult

Background: Outcome of Mycobacterium tuberculosis (Mtb) infection is affected by virulence of the infecting strain of Mtb, host environment, co-morbidities, and the genetic composition of the host, specifically the presence or absence of genes involved in immune responses/regulation. It is hypothesized that specific killer immunoglobulin-like receptor (KIR) genes may be associated with Mtb infection and clinical outcome. This cross-sectional study examined the KIR gene frequencies, profiles, and haplotypes of individuals with active tuberculosis, latent tuberculosis infection, compared to TB and HIV negative healthy controls.
Results: Analysis of KIR gene frequencies revealed differences among disease status groups, suggesting that enrichment or depletion of specific KIR genes may direct the disease outcome. Mtb infected individuals were more likely to have a centromeric-AA haplotype compared to controls.
Conclusion: The differences in KIR gene frequencies and haplotypes may result in differential cytokine expression, contributing to different disease outcomes, and suggest a genetic influence on Mtb susceptibility and pathogenesis.

Semin Respir Crit Care Med. 2013 Feb;34(1):67-86. (PMID: 23460007)
Methods Mol Biol. 2008;415:49-64. (PMID: 18370147)
Annu Rev Immunol. 2001;19:93-129. (PMID: 11244032)
Nucleic Acids Res. 2011 Jan;39(Database issue):D913-9. (PMID: 21062830)
PLoS Genet. 2005 Aug;1(2):129-39. (PMID: 16132082)
Scand J Immunol. 2012 Nov;76(5):491-6. (PMID: 22862677)
J Infect Dis. 2002 Dec 15;186(12):1808-14. (PMID: 12447767)
Indian J Med Res. 2004 Oct;120(4):213-32. (PMID: 15520479)
Iran J Immunol. 2012 Mar;9(1):39-47. (PMID: 22426166)
Monaldi Arch Chest Dis. 2008 Mar;69(1):24-31. (PMID: 18507196)
Annu Rev Genomics Hum Genet. 2006;7:277-300. (PMID: 16824023)
Nucleic Acids Res. 2010 Jan;38(Database issue):D863-9. (PMID: 19875415)
PLoS One. 2013;8(7):e67842. (PMID: 23861818)
J Immunol. 2000 Dec 1;165(11):6416-21. (PMID: 11086080)
Methods Mol Biol. 2012;882:391-414. (PMID: 22665247)
Hum Immunol. 2013 Jan;74(1):85-92. (PMID: 23073291)
Tuberculosis (Edinb). 2004;84(5):317-26. (PMID: 15207807)
PLoS One. 2011;6(2):e16656. (PMID: 21339808)
Immunology. 2010 Jan;129(1):8-19. (PMID: 20028428)
J Immunol. 2002 Nov 1;169(9):5118-29. (PMID: 12391228)
J Leukoc Biol. 2011 Aug;90(2):377-88. (PMID: 21642391)
J Infect Dis. 2002 Nov 15;186(10):1463-8. (PMID: 12404162)
Int J Tuberc Lung Dis. 2011 Dec;15(12):1688-91. (PMID: 22118180)
Tissue Antigens. 2006 Nov;68(5):386-9. (PMID: 17092251)

0 (Receptors, KIR)

Date Created: 20150617 Date Completed: 20160113 Latest Revision: 20181113

20231215

PMC4467048

10.1186/s12863-015-0224-x

26077983